Both West Syndrome (WS) or Infantile Spasms (IS) and Lennox-Gastaut Syndrome (LGS) have been considered catastrophic epilepsies and in some cases difficult to control, especially the latter.

Background/Aim: Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of Pharmaceutical-Grade Synthetic Cannabidiol on a range of Brain Tumours Patients and Methods: We analysed the data routinely collected as part of our treatment program in 11 Brain Cancer patients over a four- year period. Results: Clinical responses were seen in all of these 11 patients, including a reduction in tumour size, as shown by repeat scans. There were no side effects of any kind observed when using Pharmaceutical-Grade Synthetic Cannabidiol. Pharmaceutical-Grade Synthetic Cannabidiol was supplied by STI Pharmaceuticals. Conclusion: Pharmaceutical-Grade Synthetic Cannabidiol is a candidate for treating glioma patients.

The paper reflects an image of Alzheimers disorders in Asia as the largest continent of the world. Asia with increasing life expectancy and elderly people is facing Alzheimers disorders within the emerging aging people leaving behind various issues. Aging in Asia is also in parallel with poverty and health deficiency. Many parts of Asia is getting aged before becoming rich. Spread of Alzheimers disorders while needing more and additional capital to invest, is in low position. Under such circumstances, the countries of the region need new paradigms and policies to combat the emerging Alzheimers within the aging cohorts. Aging as a new phase of life needs new strategies to put into effect, to take care of those involved with Alzheimers disorders. Aging as a new part of life needs more scientific study, and the practice of plans to modify the issue.

We hypothesized that cerebral alterations in edema, perfusion, and/or intracranial pressure (ICP) are related to the development of acute mountain sickness (AMS).